- $1.84bn
- $1.82bn
- $105.97m
Brief: Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171
Zymeworks Inc reports results for the quarter ended in March - Earnings Summary
Brief: Zymeworks Q1 Operating Expenses USD 47.832 Million
Zymeworks Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Zymeworks Removed Dr. Christopher Astle From Positions Of Senior Vice President And CFO On March 31
Brief: Zymeworks Announces Appointment Of Dr. Neil Gallagher To Board Of Directors
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria'S Secret & Co
Zymeworks Inc reports results for the quarter ended in December - Earnings Summary
Brief: Zymeworks Reports Fourth Quarter Financial Results
Brief: Zymeworks Q4 Operating Expenses USD 40.347 Million
Brief: Zymeworks Sees Cash Runway Into H2 2027
Brief: Zymeworks Announces Additional Leadership Appointments
Brief: Zymeworks Announces $50 Million Private Placement To Ecor1 Capital
Brief: Zymeworks Q3 Adjusted EPS USD -0.38 Vs. IBES Estimate USD -0.47
Zymeworks Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Zymeworks Announces New Director Nominee
Brief: Zymeworks Unit & Beigene Entered Into Termination Agreement For License And Collaboration Agreement Of Zanidatamab Zovodotin
Zymeworks Inc reports results for the quarter ended in June - Earnings Summary
Brief: Zymeworks Inc. Q2 adjusted EPS USD -0.75